Leading R&D in China.
Hansoh has two R&D centers in Lianyungang, Jiangsu and Zhangjiang, Shanghai. We conduct substantially all of our R&D activities in-house. Our in-house R&D activities span the entire R&D process, including chemical compound design and screening, pharmacological and toxicological studies, chemical and manufacturing control (CMC), as well as clinical development. We have national-level research and development designations, including the National Technology Center, Post-doctoral Research Station, and Key National Laboratory. Our R&D centers also provides training programs for provincial-level academic workstations, including over ten R&D platforms such as the National and Local Joint Center for Biopharmaceutical Development, the Academician Workstation of Jiangsu, the Technology Research Center for Gastrointestinal Pharmaceutical in Jiangsu, and the Key Laboratory of Biopharmaceuticals in Jiangsu, and established long-term cooperative relationships with a number of domestic research institutes.
We focus on clinical-need based and market oriented R&D, which targets and identifies pharmaceuticals that have the potential for gaining widespread market acceptance within China’s fastest growing, large and underserved therapeutic areas, such as CNS, oncology, anti-infectives, diabetes, gastrointestinal, cardiovascular, and so on.
Hansoh established 2 R&D centers to develop bio-products, generics and innovative products.